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A B S T R A C T
Purpose: To evaluate clinical outcomes, quality-adjusted life years (QALY), cost effectiveness and cost
utility associated with VNS therapy in children with refractory epilepsy in a developing country.
Methods: Retrospective review of all children who underwent VNS implantation at King Abdullah
University Hospital and Jordan University Hospital in Jordan.
Results: Twenty eight patients (16 males) had implantation of the VNS therapy system between the
years 2007 and 2011. Mean age at implantation was 9.4 years. Mean duration of epilepsy prior to
implantation was 6.5 years. The most common seizure type was generalized tonic clonic seizures. Fifteen
patients showed a 50% or more reduction in seizure frequency. There was a signiﬁcant reduction in total
number of seizures (p = 0.002) and emergency room (ER) visits (p = 0.042) after VNS therapy. Atonic
seizures were more likely to respond than generalized tonic clonic seizures, p = 0.034. Direct hospital
costs prior to VNS implantation were analyzed in relation to ER visits and intensive care unit (ICU)
admissions. Cost savings per patient did reduce the ﬁnancial burden of the device by about 30%. There
was a QALY gain per lifetime of 3.78 years for children and 1 year for adolescents.
Conclusion: Response to VNS implantation in Jordan was favorable and similar to what has been
previously reported. QALY gain and cost per QALY analysis were encouraging. Cost savings were related
to reduction in seizure severity. In circumstances of limited resources as in developing countries,
targeting patients with frequent utilization of health services would improve cost effectiveness.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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From its approval by the FDA in 1997 for the treatment of
refractory partial epilepsy, the vagus nerve stimulation (VNS)
therapy system has been implanted in over 100,000 patients
worldwide.1 Numerous reports have established VNS therapy as a
safe and effective treatment option for children and adults who
have refractory epilepsy.1–6 The cost effectiveness of VNS therapy
has also been assessed and established in the developing world, 7,8
however there are very little reports on its use in developing
countries,9 and none that address cost related issues. In this report,
we describe the experience with VNS therapy in children with* Corresponding author at: Faculty of Medicine, Jordan University of Science and
Technology, P O Box 3030, Irbid 22110, Jordan. Tel.: +962 2 795498829;
fax: +962 2 7201064.
E-mail addresses: Samahk72@yahoo.com (S.K. Aburahma), ﬁras@just.edu.jo
(F.Q. Alzoubi), hmhammouri@just.edu.jo (H.M. Hammouri),
masriamira69@hotmail.com (A. Masri).
http://dx.doi.org/10.1016/j.seizure.2014.10.014
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rerefractory epilepsy from the two major university hospitals in
Jordan, and perform an analysis of direct hospital costs and cost
utility.
2. Materials and methods
This is a retrospective review of all children who underwent
VNS implantation at King Abdullah University Hospital, and Jordan
University Hospital. King Abdullah University Hospital is an urban,
JCIAa accredited, tertiary referral hospital in the north of Jordan,
and Jordan University Hospital is a JCIA accredited tertiary referral
hospital in the capital Amman. Detailed clinical evaluation, brain
magnetic resonance imaging results, and electroencephalography
results were collected for all patients. Parents were instructed to
keep seizure diaries for at least two months prior to implantation
of the device, and to continue with the diaries after implantation.a JCIA: Joint Commission International Accreditation.
served.
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complications of VNS therapy were collected every visit, as was
data regarding the child’s behavior, alertness, and interaction.
Seizure severity was assessed by duration of seizures, intensity of
convulsive phenomena, loss of posture or injury during seizures,
frequency of status epilepticus episodes, duration of postictal
phenomena, and speed of recovery. The McHugh VNS speciﬁc
outcome scale was utilized for assessment of seizure frequency
and severity after implantation.10
Data regarding frequency of emergency room visits, ward
admissions, and intensive care unit admissions pre and post VNS
implantation was collected retrospectively from patients’ medical
records and from caregivers.
QALY was calculated as the product of age speciﬁc life
expectancy and average utility scores. Utility scores utilized were
determined using data from Forbes et al.11 A utility score of 0.848
was assigned to the months where patients’ seizure frequency was
less than once a month, and a utility score of 0.681 was assigned to
the months where patients’ seizure frequency was more than once
a month. A utility value of 0.285 was assigned to patients with
more than 50% reduction in seizure frequency. QALY was
calculated for the 6 months prior to VNS implantation and the
total post VNS period. Cost per QALY was calculated by dividing net
cost (total cost minus costs averted) by the number of QALYs
gained over a six year period (assuming battery life of 6 years).Table 1
Clinical characteristics of children who underwent VNS implantation.
Pt Seizures Etiology Epilepsy
durationa
VNS
agea
Follow
upa
1 FS Cerebral
calciﬁcations
5 9 5.5 
2 FS Unknown 9 15 6.5 
3 A Perinatal
insult
6 6 5 
4 FS Unknown 3 8.5 5 
5 A PVL 3 4 6 
6 GTC Unknown 9 16 6.5 
7 FS Bilateral
MTS/Dravet
2 2.5 4.5 
8 GTC, M,A Pachygyria 16 16 5 
9 FS Unknown 5 9 3 
10 GTC, A Dravet 5 6 4 
11 FS Unknown 5 13 5 
12 GTC, M,A Unknown 2 3 5 
13 GTC Unknown 9 11 5 
14 FS Unknown 9 10 5.5 
15 GTC,A Dravet 1 2 5 
16 FS,M Ischemic
stroke
3 9 4.5 
17 FS,GTC Unknown 5 6 6 
18 GTC Unknown 8 9 5 
19 GTC Unknown 3 5 6 
20 GTC,FS Brain RTX 10 13 5.5 
21 GTC,A Unknown 3 5 6 
22 GTC,A Brain atrophy 7 8 5.5 
23 GTC,A Unknown 14 15 5.5 
24 FS CD/postop 11 12 5 
25 FS CD 13 19 6.5 
26 FS Unknown 2 11 4.5 
27 GTC Unknown 5 9 3.5 
a In years.
FS: focal seizures, A: atonic, GTC: generalized tonic clonic, M: myoclonic, PVL: periventri
dysplasia.The study was approved by the ethics committee.
3. Statistics
Statistical summaries were used to describe dependent and
predictor variables. An ordinal logistic regression was utilized
when dependent variables were counts, and was ﬁtted for
comparisons between the pre and post VNS periods regarding
number of seizures and ER visits. ANOVA and correlations were
utilized when the dependent variables were continuous; ANOVA
was ﬁtted for evaluating the effect of gender and seizure type on
seizure frequency reduction, and correlations with conﬁdence
intervals of 95% were calculated to evaluate the effect of age of
epilepsy onset, age at VNS surgery, and duration of epilepsy on
seizure frequency reduction. When multiple comparisons were
needed (e.g. effect of different seizure types on seizure frequency
reduction) Tukey HD method was used. JMP software was utilized
for analysis with a = 0.05.
4. Results
4.1. Patient characteristics
Twenty eight patients (16 males) had implantation of the VNS
therapy system between the years 2007 and 2011, Table 1. OneSeizure
frequency
reduction
Seizure
frequency
after VNS
Seizure severity
reduction
100% None
>90% Once/few months Rapid recovery
Shorter seizures
>90% Once monthly Abolished drops
>90% <once monthly Rapid recovery
>90% <once monthly
70–90% Twice/month Rapid recovery
No status
70–90% <once monthly Rapid recovery
No status
70% Twice/week Abolished drops
70% Once/10 days
70% 4 sz/week Abolished drops Non
convulsive, rapid
recovery
50% Weekly Rapid recovery
50% Daily brief Abolished drops, shorter
GTC, rapid recovery
50% Twice/week Rapid recovery
50% Twice/week Abolished daytime seizures
50% Weekly Abolished drops, rapid
recovery
50% Once/week Shorter seizures
30% Once/week Rapid recovery,
nonconvulsive
30% 4 sz/week
30% Twice/week Abolished daytime
seizures
None Daily
None Once/week Device removed
None Daily
None Twice/month
None Daily Device removed
None Daily
None Once/week Device turned off
None Once/week
cular leukomalacia, MTS: mesial temporal sclerosis, RTX: radiotherapy, CD: cortical
Table 2
Epilepsy syndromes in children with VNS implantation.
Epilepsy syndrome Number of patients
Lennox Gastaut syndrome 8
Focal epilepsy/unknown etiology 7
Symptomatic focal epilepsy 6
Generalized epilepsy/unknown etiology 2
Dravet syndrome 2
Myoclonic astatic epilepsy 1
GEFS+ 1
GEFS+: generalized epilepsy with febrile seizures plus.
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shortly after implantation, of causes unrelated to his underlying
condition or the device. Mean age at implantation was 9.4 years
(2–19). Mean duration of epilepsy prior to implantation was 6.5
years. The most common seizure type was generalized tonic clonic
seizures, followed by focal seizures, and atonic seizures, (14, 13,
and nine patients respectively). Eleven patients had mixed
seizures. The most common epilepsy syndrome was Lennox
Gastaut syndrome (eight patients), followed by focal epilepsy of
unknown etiology (seven patients), and symptomatic focal
epilepsy (six patients), Table 2. Dravet syndrome was diagnosed
in two patients. Sixteen patients had mental retardation. All
patients had failed to respond to at least four antiepileptic
medications, and all were on multiple antiepileptic medications at
the time of implantation.
4.2. Device implantation
Device implantation at King Abdullah University Hospital was
performed by otolaryngology service by the same team (23
patients), while the remaining ﬁve devices at Jordan University
Hospital were implanted by neurosurgery service. Review of
operative notes showed mean operative time for VNS implantation
was 80 min. No signiﬁcant intraoperative complications were
reported, namely no signiﬁcant blood loss or cardiac adverse
events.
The VNS device was switched on two weeks after surgery for all
patients. Initial settings were: output current 0.25 mA, frequency
30 Hz, pulse width of 250 ms, on-time 30 s, and off-time 5 min.
Thereafter output current was increased every two to four weeks
by 0.25 mA to a target output of 1.75–2.25 mA according the
patient response. Duty cycle changes were performed according to
seizure outcome and patient tolerance.0
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Fig. 1. Improvement over tim4.3. Seizure outcome
Follow up data was available for all patients. All patients were
followed for a minimum of three years, 22 patients had follow up of
ﬁve or more years. After 3 years of VNS therapy, seizure outcome was
rated as McHugh’s class I (80–100% reduction in seizure frequency)
in seven patients, class II (50–79% reduction in seizure frequency) in
nine patients, class III (<50% reduction in seizure frequency) in four
patients, and class V (no improvement) in seven patients. None of the
patients experienced signiﬁcant beneﬁt from activating the device
by the magnet (class IV). All patients in class I and II showed
signiﬁcant reduction in ictal and postictal activity (McHugh’s class IA
and IIA).
Most patients with 50% or more reduction in seizure frequency
showed improvement within nine months of device implantation,
Fig. 1. This improvement stabilized by 18–24 months. Both
patients with Dravet syndrome showed signiﬁcant reduction in
seizure frequency, abolished drop attacks, reduction in seizure
severity, and improved alertness and communication. However,
there was no statistically signiﬁcant effect of epilepsy syndrome on
seizure frequency reduction, Fig. 2.
The overall mean number of seizures per month showed a
signiﬁcant reduction from 85.7 seizures/month pre VNS to
16.1 seizures/month post VNS, (p = 0.0022). Comparing the mean
reduction in number of seizures between the three major seizure
types (generalized, focal, and atonic), there was a mean reduction
of 25.9 seizures/month for generalized tonic clonic seizures,
74.2 seizures/month for focal seizures, and 90.2 seizures/month
for atonic seizures. Utilizing Tukey method for multiple compar-
isons, there was a signiﬁcant difference in reduction means
between atonic and generalized tonic clonic seizures, with a
difference in means of 64.3 seizures/month, (p = 0.0377).
4.4. QALY gained after VNS implantation
Data regarding life expectancy in Jordan was obtained from the
WHO Global Health Observatory Data Repository (http://apps.-
who.int/gho/data). Table 3 summarizes the results of QALY
analysis. For children aged 1–9 years the average gain in QALY
was 3.78 years over lifetime, and for adolescents aged 10–19 years
the average gain in QALY was 1 year over lifetime.
4.5. Direct hospital costs and cost utility analysis
Direct hospital costs prior to VNS implantation were calculated
in relation to ER visits and ICU admissions. There was a signiﬁcant20 25 30 35
on ths
e after VNS implantation.
Table 4
Adverse events with VNS therapy.
Adverse events No. of patients
Cough 7
Shortness of breath 7
Hoarse voice 6
Dysphagia 4
Weight loss 7
Stuttering 1
Behavioral problems 2
Fig. 2. Side by side boxplot of seizure frequency reduction (SFR) vs epilepsy
syndrome. LGS: Lennox Gastaut syndrome, SF: symptomatic focal, UF: unknown
etiology focal.
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relative to pre VNS (0.73 vs 3.0 respectively, p = 0.042). In 5
patients who had frequent status epilepticus events, the total
number of intensive care unit admissions dropped from 13
admissions in the 3 years prior to implantation to none in the
last 3 years after implantation.
In Jordan, ER visits to ministry of health hospitals cost an
average of 10 US dollars, including cost of labs and possible
administration of IV diazepam, or the cost of attending to a head
laceration in cases of atonic seizures. In the two university
hospitals where the patients were recruited for this study an ER
visit costs around 20 US dollars. For the patients who showed a
signiﬁcant drop in ER visits after implantation, the calculated total
direct hospital costs related to ER visits in the six months prior to
implantation was around 7200 US dollars. Estimating that without
implantation these patients would continue to have the same
frequency of ER visits, cost savings for these patients after
implantation was calculated assuming a battery life of a minimum
6 years. Using this calculation, total savings related to reduction in
ER visits amounted to around 86,400 US dollars. Regarding ICU
admission costs, the cost of ICU admission per day was calculated
to be an average of 500 USD. From medical records total number of
days in ICU for all patients was 37 days over the 3 years prior to
VNS implantation, and none after implantation. Using this
calculation, costs averted from decreased ICU admissions was
calculated to be 18,500 USD. Total costs savings from decreased ER
visits and ICU admissions was 104,900 USD. Divided by the total
number of patients, there was a savings of 3885 USD per patient.
VNS implantation therapy in Jordan costs an average of 12,000 USD
per patient.
To calculate cost per QALY gained, patients with more than 50%
reduction in seizure frequency were assigned a utility value of
0.285 (time trade off experiments by Forbes et al.). Applying this to
the 15 patients with more than 50% reduction in seizure frequency,
and a battery life of 6 years (none of our patients with more than 5Table 3
Quality adjusted life years gained over life time for all VNS patients.
Group (n) Life expectancy
(yrs)
Pre VNS
utility score
Pre
QA
1–9 yrs (16) 72 0.681 49 
10–19 yrs (11) 62.5 0.681 42.
QALY: quality adjusted life years.
yrs: years.years follow up required change in battery), and using the total
cost savings of 104,900 USD, cost per quality adjusted life years
was 4089 USD per successful device.
4.6. Complications and adverse events
One patient had intraoperative oozing. Two patients had
postoperative infection within the ﬁrst week of implantation
and were treated with intravenous antibiotics. One of these
patients eventually required removal of the device because of
recurrent methicillin resistant staph aureus infection. One patient
had wound dehiscence one week after surgery that was surgically
treated, and one patient required repositioning of the device due to
prominence of the device and neck leads. One patient required
reimplantation of the device due to electrode failure.
The most common device related adverse events were cough,
shortness of breath, and weight loss, Table 4. Weight loss related to
decrease oral intake was reported in seven patients, and was
signiﬁcant in ﬁve. Three of these patients had normal intelligence
and reported decreased appetite. Analgesics did not improve oral
intake in the noncommunicative patients, and in one patient
decreasing the stimulation intensity did help. Two patients with no
beneﬁt from the device and signiﬁcant weight loss had the device
either removed or turned off with subsequent increase in oral
intake and weight.
5. Discussion
At the two major university hospitals in Jordan, between 2007
and 2011, 28 patients underwent VNS therapy implantation for
refractory epilepsy. Retrospective review of these patients showed
that in 59%, there was a reduction in seizure frequency of 50% or
more after a mean follow up of three years, with a statistically
signiﬁcant reduction in total number of seizures per month. These
results are similar to those in previous reports on VNS therapy in
children with epilepsy.1,16–18
In this report, there was no signiﬁcant correlation between
epilepsy syndrome and seizure frequency reduction, however,
atonic seizures were more likely to respond to VNS therapy when
compared to generalized tonic clonic seizures. Predictors of seizure
freedom with VNS therapy have not been consistent and at times
conﬂicting,19–22 however several reports have shown a favorable
response of drop attacks to VNS therapy.18,23,24 Other reports have
highlighted the particular efﬁcacy of VNS implantation in speciﬁc VNS
LY (yrs)
Post VNS
utility score
Post VNS
QALY
QALY
gained (yrs)
0.733 52.78 3.78
5 0.696 43.5 1
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thies.16,18,25 Our observation of progressive improvement in
seizure control in the ﬁrst 24 months after implantation with
subsequent plateau of effect is similar to previous observa-
tions.2,26,27
This is one of the ﬁrst reports on QALY gain after VNS
implantation.28 There was a QALY gain of about 378 years for 100
children and 100 years for 100 adolescents. This is signiﬁcantly
more than QALY gain reported by Messori et al. for patients
treated with lamotrigine29, but signiﬁcantly less than the QALY
gain reported by Helmers et al.28 As reported by Helmers et al.,
their estimate of QALY gain is probably an overestimation due
to the fact that they utilized hospitalizations and ER visits as
proxies for seizure occurrences. This was a small sample of
patients; however data regarding seizure frequency and severity
was directly available for all patients for utilization in QALY
analysis. In this group, children gained more QALYs than
adolescents, related to the fact that most patients with less
than one seizure per month post implantation were within this
age group, and a higher life expectancy for this age group.
Limiting our QALY analysis is the fact that utility scores
developed by Forbes et al. were used11; these utility scores
were deduced for adults with refractory epilepsy in a developed
country. Indeed, in any case, attempting to deduce utility values
for children with refractory epilepsy, who have cognitive
challenges, using currently available instruments (EQ-5D, time
trade off, etc.. . .) would be compromised given that parents must
act as proxies for completion of these exercises.
It has been shown that VNS therapy is cost effective in
developed countries.7,8 Helmers et al. showed that cost savings
started to outweigh the average total costs of the VNS device and
implantation procedure after 1 year for adolescents and 1.5 years
for children.28 In this group of patients, direct hospital costs
savings was related to reduction in seizure severity with signiﬁcant
reduction in ER visits and ICU admissions. Complications such as
hospitalization for infections were not included in our analysis; in
the report by Forbes et al., up to a 10% complication rate did not
lead to a signiﬁcant increase in cost per QALY.11
Despite not reaching the cost savings seen in developed
countries, the ﬁnancial burden of the device was reduced by
about 30% per patient, and cost per QALY for successful devices was
around 4000 USD per successful device. Factors leading to
limitation in direct cost savings in our group of patients include
the low cost of medical care, the fact that only a margin of the care
provided in developed countries is available, and VNS implantation
costing approximately the same as in developed countries.
Although cost per QALY was lower than that reported by Helmers
et al., it is difﬁcult to interpret this value as the optimal threshold
for cost effectiveness in Jordan or similar developing countries has
not been previously determined. This low cost per QALY however is
consistent with the sensitivity analysis performed by Forbes et al.
that showed lower cost per QALY if the battery life was increased to
6 years, or if response rate was more than 1 in 6 patients; in this
report almost 1 in 2 patients showed a 50% improvement in seizure
frequency.
Epilepsy surgery, with its cost and infrastructural requirements,
continues to be an unattainable option for most patients with
refractory epilepsy in Jordan, and most of the developing
world.12,13 There have been several reports demonstrating
successful models for epilepsy surgery in developing countries
utilizing technology and expertise reasonably available in the
developing world.13–15 However, these reports have understand-
ably been on adults, for highly selected patients with straightfor-
ward intractable temporal lobe epilepsy. Efforts at establishing
successful epilepsy surgery programs in most developing countries
continue to be hampered by limited sustained resources and attimes by factors such as poor adherence to capability by medical
personnel.
It is easy to appreciate the attractiveness of the VNS therapy
system in such a setting; it is a relatively uncomplicated surgical
procedure that is not technologically demanding. In the absence of
epilepsy surgery as a viable option, the preoperative investigations
are aimed at conﬁrming the presence of refractory epilepsy which
can be achieved by available noninvasive procedures.
In developing countries like Jordan no policies exist for ﬁnancial
coverage of VNS implantation, there is continued skepticism
regarding the cost of the device, and allocation of limited resources
is necessary. This analysis shows it might be reasonable to propose
to initially target patients with refractory epilepsy who have
frequent utilization of health care resources (e.g. frequent status
epilepticus, frequent admissions, and frequent ER visits for drop
attacks and associated injuries), where the device shows the most
cost savings. Although this might sound like treatment rationing,
in reality it is a means to provide more patients with refractory
epilepsy with a much needed therapy.
The interpretation of our observations was naturally limited by
the retrospective nature of the analysis, small number of patients,
and selection bias of children with refractory epilepsy regarding
implantation. QALY analysis and cost effectiveness were based on
utility scores previously deduced on a different population of
patients. Studies assessing appropriate means for arriving at utility
values for children with refractory epilepsy are needed, as are
studies assessing incremental cost effectiveness ratios with control
populations.
In conclusion, VNS implantation in Jordan was found to be
feasible, effective and well tolerated. Cost utility analysis was
encouraging, with improving cost effectiveness and cost utility
expected if targeted patient selection is implemented.
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